Appl No. 10/666,490 Amdt. Dated January 27, 2006 Reply to Office Communication of December 29, 2005

Docket NO CEN0312NP

In the Specification:

Please amend the specification as follows:

(a) remove blank lines on page 5, lines 14-16,

In another aspect, the invention provides isolated nucleic	acid molecules encoding a(n) 1L18 or 1L-
18R protein having an amino acid sequence as encoded b	y the nucleic acid contained in the plasmid
deposited as designated clone names	and ATCC Deposit Nos.

(b) delete extra "()" in phrase "95%-1000%" on page 14, line 13:

preferably at least 80%, 90%, or 95%-1000% of that of the native (non-synthetic), endogenous or related

(c) change "TNF-" at page 30, line 33-35, to TNF-alpha:


TNF-alpha \boxminus with high affinity and possess low immunogenicity). A functional equivalent of TNF receptor molecule also includes modified TNF receptor molecules that functionally resemble TNF receptor molecules that can be used in the present invention (e.g., bind TNF-alpha \boxminus with high affinity and possess

(d) change "www.copewithcytokines.com" to <u>www.copewithcytokines.de</u>, at page 31, line 5:

Cytokines include any known cytokine. See, e.g., CopewithCytokines.de com. Cytokine

On page 45, lines 1-21, please amend as follows:

1



Initial amino acid numbering refers to the positions in IL-1 and the IL-1 receptor. Once the IL-18/IL-18 receptor structure was complete, the structure was renumbered to be consistent with IL-18/IL-18 receptor numbering. The amino acids in IL-1 were electronically mutated to the IL-18 sequence. Additions or deletions were ignored at this point.

_